New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:17 EDTJNJEarnings Preview: J&J investors will focus on catalysts, operating leverage
Johnson & Johnson (JNJ), a diversified, global healthcare conglomerate, is scheduled to report fourth quarter earnings before the open on Tuesday, January 21, with a conference call scheduled for 8:30 am ET. EXPECTATIONS: Analysts are looking for EPS of $1.20 on revenue of $17.95B, according to First Call. The consensus range for EPS is $1.19-$1.22 on revenue of $17.82B-$18.09B. LAST QUARTER: Johnson & Johnson reported Q3 adjusted EPS of $1.36 against estimates for $1.32 on revenue of $17.6B against estimates for $17.46B. At the time of its Q3 earnings release, J&J also raised its FY13 EPS view to $5.44-$5.49 from $5.40-$5.47. STREET RESEARCH: In a note to investors on January 7, RBC Capital said it expects the company's pharmaceutical franchise to continue to deliver above industry average revenue growth, and it predicts that the company will continue to have operating leverage, enabling its EPS to surpass consensus levels over the next several years. The firm raised its price target on J&J to $104 from $88. On January 10, Barclays downgraded shares of J&J to Equal Weight from Overweight. Barclays downgraded Johnson & Johnson citing limited catalysts and valuation.The firm kept its price target remains $99. PRICE ACTION: Since its last earnings report, shares of J&J are up approximately 5%. Over the last year, shares are up over 30%.
News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
08:27 EDTJNJJanssen Affiliate Cilag acquires Covagen, terms not disclosed
Subscribe for More Information
07:03 EDTJNJVIVUS acquires patents from Janssen Pharmaceuticals
VIVUS (VVUS) announced the acquisition of a group of patents from Janssen Pharmaceuticals (JNJ) covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions. Janssen has agreed to dismiss the lawsuit it brought against VIVUS on August 22, 2014 in the U.S. District Court for the District of Delaware. VIVUS will pay a one-time upfront fee and a royalty to Janssen on Qsymia product sales for an assignment of these topiramate-related patents owned by Janssen. VIVUS has an option to buy out the royalty for a predetermined amount.
August 21, 2014
05:42 EDTJNJIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 18, 2014
11:41 EDTJNJCubist rises after report sparks takeover interest speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use